|
 |
XifaxanThis page contains recent news articles, when available, and an overview of Xifaxan but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The company's Xifaxan treats hepatic encephalopathy, or HE, and irritable bowel syndrome, which is among the most common chronic medical problems, ... Wall Street Journal Early-Market Movers: Tenet Healthcare, Las Vegas Sands - 06 Jan 2010 ...the company their top small cap pick for 2010 citing Street estimates which underestimate the revenue potential of its Xifaxan gastrointestinal treatment. FOXBusiness US HOT STOCKS: Ford, Tenet Healthcare, RadioShack, Kraft - 06 Jan 2010 ...their price targets to reflect lofty expectations for drug Xifaxan, leading one to call Salix its top small-cap specialty pharmaceutical pick in 2010. ... Wall Street Journal Benzinga's Volume Movers (SLXP, CAAS, WPRT, TKTM, HRBN) - 06 Jan 2010 SLXP's shares moved up sharply after analysts at Piper Jaffray said that street consensus underestimates the revenue potential of the Xifaxan ... Benzinga Watchlist and Market Preview for January 5, 2010 - 06 Jan 2010 The analyst believes that the market is significantly underestimating the pricing power associated with Xifaxan in its expansion markets. ... Sumfolio.com Bank of America, OTIV, SLXP, CBY, KFT, BRK.A, ZMH, KCI Popular Stocks - 06 Jan 2010 ...their price targets to reflect lofty expectations for drug Xifaxan, leading one to call Salix its top small-cap specialty pharmaceutical pick in 2010. ... Ub News Gains for airlines but contradictory data prompt caution - 06 Jan 2010 Wall Street has underestimated the potential revenues from the group's Xifaxan gastrointestinal treatment, the research group said. ... Financial Times Ford, Ciena, Melco, Merix, ResMed, Sears: US Equity Movers - 06 Jan 2010 Inc., which cited the pricing power of its Xifaxan drug. Sears Holdings Corp. (SHLD US) added 4.5 percent to $87.20, the highest price since October 2008. ... BusinessWeek STOCKS NEWS US-Ciena calls active on takeover chatter-analysts - 06 Jan 2010 Pharmaceuticals Inc rose on Tuesday after a pair of brokers raised their price targets on the stock, citing potential from the company's drug Xifaxan. ... Interactive Investor Salix Pharmaceuticals Reports Concurrence with FDA on Content and Format of ... - Dec 10, 2009 Rifaximin tablets 200 mg, which Salix markets in the United States under the trade name XIFAXAN ® (rifaximin) tablets 200 mg, currently is approved for the ... PharmaLive.com (press release) Salix Beats on Xifaxan Strength - Nov 11, 2009 Xifaxan continued to perform well with revenue almost doubling to $42.7 million. We believe wholesaler stocking, price increases and prescription growth ... Zacks.com UPDATE 1-Salix posts narrower-than-expected Q3 loss - Nov 9, 2009 O) posted a narrower-than-expected quarterly loss as revenue from its traveller's diarrhoea drug Xifaxan doubled, but forecast fourth-quarter loss wider ... Reuters Salix Pharmaceuticals Previews American College of Gastroenterology 2009 ... - Oct 26, 2009 Rifaximin tablets 200 mg, which Salix markets in the United States under the trade name XIFAXAN® (rifaximin) tablets 200 mg, currently is approved for the ... Reuters Salix Pharmaceuticals Reviews American Association for the Study of Liver ... - Nov 2, 2009 Rifaximin tablets 200 mg, which Salix markets in the United States under the trade name XIFAXAN ® (rifaximin) tablets 200 mg, currently is approved for the ... WELT ONLINE Salix Pharmaceuticals Gets Intellecutual Property Relating to Rifaximin - Nov 6, 2009 SpA, to use, sell, have sold and import licensed rifaximin products, which the Company markets in the United States under the trade name XIFAXAN. ... Trading Markets (press release) Salix Pharmaceuticals Secures Additional Intellecutual Property Relating to ... - Nov 3, 2009 Salix markets XIFAXAN® (rifaximin) tablets 200 mg, OSMOPREP® (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, ... Reuters Salix Pharmaceuticals to Present at Credit Suisse Conference - Nov 4, 2009 Salix markets XIFAXAN® (rifaximin) tablets 200 mg, OSMOPREP® (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, ... Reuters In Which I Solve This Ground Beef E.Coli Problem for Good - Oct 23, 2009 After several days of antibiotics (Gd bless you, Xifaxan!), I'd turned the corner and was starting to eat solid food again. Some people haven't been so ... The Faster Times Salix Pharmaceuticals, Ltd. - Pharmaceuticals & Healthcare - Deals and ... - Nov 13, 2009 As of December 31, 2008, the Company's products were XIFAXAN (rifaximin) Tablets 200 milligram; MOVIPREP; OSMOPREP, VISICOL Tablets, AZASAN Azathioprine ... PR-inside.com (press release) Research hints at possibilities for diarrhea medication. - May 18, 2005 May 18--Eight months after Salix Pharmaceuticals started selling Xifaxan as a ... Much of the research is studying Xifaxan as a possible treatment to reduce ... Free with registration - News & Observer - AccessMyLibrary.com Salix Announces Termination of XIFAXAN(TM) Co-Promotion; Reaffirms … - Aug 22, 2005 Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced that ALTANA Pharma US and Salix Pharmaceuticals mutually have agreed to early termination of the ... RedOrbit Salix Announces Completion of First XIFAXAN(R) Travelers' Diarrhea … - Jul 10, 2008 RALEIGH, NC--(BUSINESS WIRE)--Jan. 4, 2006--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the successful completion and outcome of its first ... businesswire.com Salix Pharmaceuticals Announces XIFAXAN Co-Promotion; ALTANA … - Jul 10, 2008 RALEIGH, NC--(BUSINESS WIRE)--March 3, 2005--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has entered into a co-promotion ... businesswire.com Salix jumps on drug success - Sep 5, 2007 Salix said its drug rifaximin, which it currently sells in the United States under the brand name Xifaxan for travelers' diarrhea caused by E. coli bacteria ... Reuters … Week 2006 Update; Sunday, May 21 - XIFAXAN(R) Oral Presentation a - May 22, 2006 The 87 subjects were randomized to receive either XIFAXAN 1200 mg daily (400 mg ... XIFAXAN(R) (rifaximin) tablets 200 mg is indicated for the treatment of ... Free with registration - Business Wire - AccessMyLibrary.com … Moves Forward With XIFAXAN Travelers' Diarrhea Prevention Study - Jul 6, 2005 Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced today that it has begun enrolling and dosing subjects in a Phase III study to evaluate the efficacy and ... RedOrbit Salix Pharmaceuticals Development Update; XIFAXAN(R) Trials Initiated... - Jan 11, 2006 Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today reported that initial subjects have been enrolled and dosed in three late-stage trials designed to evaluate ... RedOrbit Salix Pharmaceuticals Announces XIFAXAN Co-Promotion; ALTANA … - Mar 3, 2005 RALEIGH, NC -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has entered into a co-promotion agreement with ALTANA Pharma US, ... Free with registration - Business Wire - AccessMyLibrary.com Shares of Salix rise on good drug news - Oct 6, 2008 Rifaximin is currently marketed as Xifaxan, a treatment for travelers' ... Salix is set to lose patent protection on that indication of Xifaxan in 2009. Bizjournals.com Salix Announces Completion of First XIFAXAN(R) Travelers' Diarrhea … - Jan 5, 2006 Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the successful completion and outcome of its first Phase III study to evaluate the efficacy and ... RedOrbit Salix Pharmaceuticals: Xifaxan potential lies in label extensions - Jan 26, 2007 By BR staff writer. Salix Pharmaceuticals' antibiotic Xifaxan was approved by the FDA for the treatment of traveler's diarrhea (TD) in 2004. ... Pharmaceutical Business Review Salix doubles 3Q profit on strong sales - Nov 6, 2007 Sales of Xifaxan, a treatment specifically for travelers' diarrhea caused by strains of the E. coli pathogen, increased slightly to $16.1 million. ... Bizjournals.com … Reports XIFAXAN Clinical Update; Rifaximin -XIFAXAN- Studied in... - Apr 25, 2005 Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that results of five investigator-initiated trials of rifaximin will be presented at Digestive ... RedOrbit Q3 2006 Salix Pharmaceuticals, Inc. Earnings Conference Call - Final. - Nov 7, 2006 XIFAXAN revenue for the third quarter of 2006 was $15.9 million, a 71% increase compared to the third quarter of 2005 and XIFAXAN revenue for the first nine ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Salix Pharmaceuticals Reports American College of Gastroenterology … - Oct 23, 2006 Subjects received either XIFAXAN 600 mg or a matching placebo daily for 14 days in ... XIFAXAN was well-tolerated with adverse events occurring in a similar ... Genetic Engineering News - Genetic Engineering News (press release) Salix Pharmaceuticals Reports 4Q2004 and FY2004 Results; Salix … - Feb 15, 2005 XIFAXAN revenue for 2004 was $9.8 million. XIFAXAN was launched in July 2004 and ... The approval of two products, XIFAXAN and COLAZAL, in a period of four ... Free with registration - Business Wire - AccessMyLibrary.com Salix Pharmaceuticals Reports 1Q2007 Results.(Financial report) - May 8, 2007 XIFAXAN([R]) revenue for the first quarter of 2007 was $15.4 million, ... Prescription demand for our bacteria-related disease product, XIFAXAN, ... Free with registration - Business Wire - AccessMyLibrary.com Antibiotic May Aid Irritable Bowel - Oct 16, 2006 ...(WebMD) Ten days' treatment with the antibiotic Xifaxan reduces symptoms of irritable ... Xifaxan, now approved for the treatment of travelers' diarrhea, ... CBS News When an Upset Stomach Roils Your Trip - Apr 18, 2008 An antibiotic called Xifaxan has been approved to treat traveler's diarrhea; ... If diarrhea-causing bugs eventually prove resistant to Xifaxan, he adds, ... New York Times Salix Pharmaceuticals Reports 1Q2005 Results; Total Product Revenue … - Mar 31, 2005 XIFAXAN(TM) revenue for the first quarter of 2005 was $2.6 million. ... "XIFAXAN continued to make gains during the first three months of 2005. ... businesswire.com Event Brief of Q2 2007 Salix Pharmaceuticals, Inc. Earnings Conference... - Aug 2, 2007 2Q07 XIFAXAN revenue was $15.8m, 52% increase vs. 2Q06. ... XIFAXAN development efforts during 2Q07 included the completion of patient enrollment in Phase ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Salix Expands XIFAXAN(R) Intellectual Property; Secures License … - Jul 5, 2006 RALEIGH, NC -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has entered into an agreement with Cedars-Sinai Medical Center, ... Free with registration - Business Wire - AccessMyLibrary.com Business & Finance; Pharma companies announce termination of Xifaxan … - Sep 20, 2005 The company is aware of 16 investigator-initiated studies of Xifaxan that ... Additionally, 32 articles and 8 abstracts on Xifaxan were published during the ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones WHAT IS XIFAXAN FOR ? - May 3, 2008 Xifaxan is an antibiotic that treats bacterial infection in the intestines. Unlike other antibiotics, it passes through the stomach and goes into your ... HealthCentral.com Salix shares surge on strong 2Q sales - Aug 8, 2006 Boosted by strong sales of Xifaxan and additional revenue from Salix's bowel-cleansing products, second quarter revenue swelled from $35.1 million a year ... Bizjournals.com Q4 2005 SALIX PHARMACEUTICALS INC Earnings Conference Call - … - Feb 24, 2006 Xifaxan revenue for the fourth quarter of 2005 was 11.6 million. Xifaxan revenue for 2005 was 30.5 million, compared to 9.8 million for 2004. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com … Publication of Study Results Suggesting XIFAXAN(TM) Potential in … - Aug 11, 2005 RALEIGH, NC -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced that results from a study published today in Current Medical Research and Opinion suggest ... $4.95 - Business Wire - ECNext Salix Pharmaceuticals to Present at Roth Capital Partners Conference. - Feb 14, 2007 Salix markets COLAZAL([R]), XIFAXAN([R]), OSMOPREP[TM], VISICOL([R]), MOVIPREP([R]), AZASAN([R]), ANUSOL-HC([R]) and PROCTOCORT([R]). ... Free with registration - Business Wire - AccessMyLibrary.com Salix Pharmaceuticals Reports American College of Gastroenterology … - Oct 23, 2006 Subjects received either XIFAXAN 600 mg or a matching placebo daily for 14 days in ... XIFAXAN was well-tolerated with adverse events occurring in a similar ... Free with registration - Business Wire - AccessMyLibrary.com Salix Pharmaceuticals Reports 1Q2005 Results; Total Product Revenue … - May 11, 2005 XIFAXAN(TM) revenue for the first quarter of 2005 was $2.6 million. ... "XIFAXAN continued to make gains during the first three months of 2005. ... $4.95 - Business Wire - ECNext Salix Pharmaceuticals Announces Issuance of Xifaxan(R) Patent. - May 18, 2006 RALEIGH, NC -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the issuance of a patent, entitled "Polymorphous Forms of Rifaximin, Processes for ... Free with registration - Business Wire - AccessMyLibrary.com Salix Pharmaceuticals announces clinical update conference call; Dr … - Oct 24, 2005 Xifaxan (rifaximin) tablets 200 mg is indicated for the treatment of patients (greater than or equal to 12 years of age) with travelers' diarrhoea caused by ... Pay-Per-View - Company Reports - Factiva, from Dow Jones Salix Pharmaceuticals announces issuance of Xifaxan(R) patent - May 19, 2006 RALEIGH, NC -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced the issuance of a patent, entitled "Polymorphous Forms of Rifaximin, Processes for Their ... carolinanewswire.com … Reflux Disease; Pharmaceutical companies team up to promote XIFAXAN - Mar 28, 2005 XIFAXAN is a nonsystemic, gastrointestinal-selective, oral antibiotic for the treatment of travelers' diarrhea caused by noninvasive strains of E. coli in ... Pay-Per-View - Gastroenterology Week - Factiva, from Dow Jones Salix Expands XIFAXAN Intellectual Property - Jun 7, 2006 RALEIGH, NC - Salix Pharmaceuticals Ltd. announced in a Thursday press release that the company has entered into an agreement with Cedars-Sinai Medical ... ag-IP-news Agency … Reflux Disease; Pharmaceutical companies team up to promote XIFAXAN - Mar 29, 2005 XIFAXAN is a nonsystemic, gastrointestinal-selective, oral antibiotic for the treatment of travelers' diarrhea caused by noninvasive strains of E. coli in ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Salix Pharmaceuticals Reports 1Q2006 Results - Mar 31, 2006 XIFAXAN revenue for the first quarter of 2006 was $6.6 million, a 153% increase ... At year-end we anticipate COLAZAL and XIFAXAN inventories will be ... businesswire.com Salix Pharmaceuticals Reports 1Q2007 Results - Mar 31, 2007 XIFAXAN ® revenue for the first quarter of 2007 was $15.4 million, ... Prescription demand for our bacteria-related disease product, XIFAXAN, increased 77% ... businesswire.com Salix Pharmaceuticals Reports American College of Gastroenterology … - Oct 23, 2006 XIFAXAN([R]), COLAZAL([R]), OSMOPREP[TM], VISICOL([R]) and MOVIPREP([R]) RALEIGH, NC -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today reported on results ... $4.95 - Business Wire - ECNext Salix Presents New Rifaximin Phase IIb Data Demonstrating Significant... - May 20, 2008 XIFAXAN is under investigation in the United States as a treatment for irritable ... In the United States, the FDA granted marketing clearance for XIFAXAN ... RedOrbit Salix' Xifaxan shows promise as CD therapy.(Salix Pharmaceuticals... - Aug 22, 2005 Salix Pharmaceuticals of the USA says that results from a recent study, published in the August issue of Current Medical Research and Opinion, indicate that ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones Positive IBS data for Salix' Xifaxan. - May 29, 2006 Positive IBS data for Salix' Xifaxan. The USA's Salix Pharmaceuticals has presented strong data on its drug candidate Xifaxan (rifaximin) at the Digestive ... $9.94 - Pharma Marketletter - Alacra Store Medical News: Irritable Bowel Syndrome - May 25, 2006 Dr. George said he and colleagues investigated Xifaxan following the ... Seven were given Xifaxan at 400 mg BID and seven were given 400 mg TID for 10 days. ... MedPage Today InKine to be bought by Salix - Jun 24, 2005 The deal will bring the total number of drugs in Salix's portfolio to six, including Colazal, Xifaxan and Azasan, which Salix already markets. ... Philadelphia Business Journal MedThink Communications Selected by Salix Pharmaceuticals to Launch … - Feb 11, 2008 XIFAXAN (rifaximin) Tablets are indicated for the treatment of patients ... XIFAXAN should not be used in patients with diarrhea complicated by fever or ... Free with registration - PR Newswire - AccessMyLibrary.com Salix to buy Philadelphia company for $190M - Jun 23, 2005 The deal will bring the total number of drugs in Salix's portfolio to six, including Colazal, Xifaxan and Azasan, which Salix already markets. ... Triangle Business Journal Personnel; Pharma company appoints VP, R&D and chief development … - Feb 11, 2005 Logan continued, "Our 2005 development programs are primarily designed to support additional uses of XIFAXAN, develop granulated mesalamine for the ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Antibiotic Aims at IBS Bloating and Global Symptoms - Oct 19, 2006 Point out that Xifaxan is a gut-selective antibiotic that is approved in the US ... The Xifaxan group also reported significantly less bloating on a visual ... MedPage Today Salix Pharmaceuticals Reports American College of Gastroenterology … - Oct 24, 2006 Clinical response occurred the first time XIFAXAN was given in 58 of 84 patients ... Clinical improvement occurred with subsequent XIFAXAN treatment in 75% ... Free with registration - Business Wire - AccessMyLibrary.com Salix Pharmaceuticals Reports American College of Gastroenterology … - Oct 23, 2006 XIFAXAN([R]), COLAZAL([R]), OSMOPREP[TM], VISICOL([R]) and MOVIPREP([R] )Sunday, October 22 Poster Presentation Highlights. $4.95 - Business Wire - ECNext Salix Pharmaceuticals Reports 4Q2006 and FY2006 Results.(Financial … - Feb 28, 2007 ..."The demand for XIFAXAN, our most compelling long-term opportunity, ... XIFAXAN sales totaled $51.6 million for the year, a 72% increase over 2005. ... $4.95 - Business Wire - ECNext Salix Pharmaceuticals Reports 2Q2006 Results. - Aug 8, 2006 XIFAXAN(R) revenue for the second quarter of 2006 was $10.4 million, ... In the near term, the growing acceptance of XIFAXAN and the introduction of ... $4.95 - Business Wire - ECNext Salix Pharmaceuticals Reports American College of Gastroenterology … - Oct 24, 2006 XIFAXAN([R]), COLAZAL([R]), OSMOPREP[TM], VISICOL([R]) and MOVIPREP([R]) RALEIGH, NC -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today reported on results ... $4.95 - Business Wire - ECNext Salix Initiates Phase 3 For Rifaximin in Non-Constipation Irritable... - Jul 1, 2008 XIFAXAN should not be used in patients with diarrhea complicated by fever ... XIFAXAN should be discontinued if diarrhea symptoms get worse or persist more ... carolinanewswire.com Rifaximin Demonstrates Highly Statistically Significant Results in … - Jun 10, 2008 XIFAXAN should not be used in patients with diarrhea complicated by fever ... XIFAXAN should be discontinued if diarrhea symptoms get worse or persist more ... Euroinvestor Salix Pharmaceuticals Reports 2Q2005 Results; Total Product Revenue … - Jun 30, 2005 XIFAXAN(TM) revenue for the second quarter of 2005 was $6.5 million, a 148% increase ... "XIFAXAN continued to gain strength during the second quarter. ... businesswire.com Morrisville, NC-based specialty drug maker earnings exceed expectation... - Nov 9, 2005 Sales of Xifaxan, an antibiotic approved to treat traveler's diarrhea, ... And to boost Xifaxan sales, Salix plans to test the drug for more uses, ... Free with registration - News & Observer - AccessMyLibrary.com This week in the medical journals - May 19, 2005 Xifaxan, a drug used to treat Escherichia coli diarrhea, may actually prevent it. ... The researchers gave students traveling in Mexico either Xifaxan or ... CNN Salix Pharmaceuticals Previews Digestive Disease Week 2007. - May 17, 2007 XIFAXAN should not be used in patients with diarrhea complicated by fever ... XIFAXAN should be discontinued if diarrhea symptoms get worse or persist more ... $4.95 - Business Wire - ECNext Salix Pharmaceuticals Reports 2Q2005 Results; Total Product Revenue … - Aug 9, 2005 XIFAXAN(TM) revenue for the second quarter of 2005 was $6.5 million, a 148% increase ... "XIFAXAN continued to gain strength during the second quarter. ... $4.95 - Business Wire - ECNext EDITED BRIEF - May 6, 2008 Combined product revenue from XIFAXAN, bowel cleansing products and other ... Record-breaking number of XIFAXAN tablets, approx. 5.3m were prescribed. ... $54.00 - Thomson StreetEvents - Alacra Store Salix shares soar on trial results, partnership, drug buy - Sep 5, 2007 The company said phase II trials of its drug Xifaxan, which is already approved to treat ... The Xifaxan data in particular was welcome news for Salix. ... Bizjournals.com Salix Pharmaceuticals Announces American College of Gastroenterology ... - Oct 16, 2006 XIFAXAN(R), COLAZAL(R), OSMOPREP(TM), VISICOL(R) and MOVIPREP(R) Studied in Investigator-Initiated and Company-Sponsored Trials. $4.95 - Business Wire - ECNext Salix Pharmaceuticals Reports 1Q2006 Results - May 4, 2006 XIFAXAN revenue for the first quarter of 2006 was $6.6 million, a 153% increase compared to the first quarter of 2005. VISICOL(R) generated revenue of $9.8 ... Genetic Engineering News - Genetic Engineering News (press release) UBC Late Stage alleges Salix Pharmaceuticals won't pay trials bills - May 2, 2008 The breach of contract case centers on trials that tested new dosages, formulations or uses for existing Salix gastrointestinal drugs Xifaxan and Colazal. ... Bizjournals.com Salix Pharmaceuticals Completes Merger with InKine Pharmaceutical; … - Oct 3, 2005 XIFAXAN(R) (rifaximin) tablets 200 mg is indicated for the treatment of ... XIFAXAN should not be used in patients with diarrhea complicated by fever or ... $4.95 - Business Wire - ECNext From 3-D to pop-ups: go dimensional: a well-delivered direct mail … - Nov 1, 2007 Each piece in the campaign drove home the benefits of Xifaxan through the graphic ... The Xifaxan campaign hits a number of key leverage points available to ... $9.94 - Pharmaceutical Executive - Alacra Store warts Immunotherapy may be a ... - May 24, 2005 THIS STUDY randomly assigned 210 adults attending summer classes in Mexico to take rifaximin (Xifaxan) or a placebo for two weeks when they first arrived. ... Pay-Per-View - Washington Post - ProQuest Archiver Salix revenue increases 51 percent. - Aug 10, 2005 Xifaxan, a treatment for traveler's diarrhea that physicians also are ... Taylor projects Xifaxan eventually will enjoy peak annual sales of more than $300 ... Free with registration - News & Observer - AccessMyLibrary.com Tuesday's Health Winners and Losers - Aug 8, 2006 Revenue rose 51% from a year ago to $52.9 million, thanks partly to Xifaxan prescription growth of 122% over the prior year. Xifaxan is indicated for the ... TheStreet.com - TheStreet.com (subscription) Salix Pharmaceuticals Reports 4Q2007 and FY2007 Results - Mar 3, 2008 XIFAXAN(R) revenue for the fourth quarter of 2007 was $17.0 million, ... XIFAXAN revenue for 2007 was $64.3 million, a 25% increase compared to 2006. ... Genetic Engineering News - Genetic Engineering News (press release) Salix Pharmaceuticals Announces Appointment of William P. Forbes, … - Jan 10, 2005 Salix markets COLAZAL(R), XIFAXAN(TM), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). A granulated mesalamine product also is under development. ... $4.95 - Business Wire - ECNext Keeping a Sell on Salix Pharma - Mar 7, 2008 While new product launches and new indications for Xifaxan should support a recovery in revenues in 2009, we do not expect earnings to recover prior to 2010 ... Zacks.com SALIX PHARMACEUTICALS INC Clinical Update Conference Call - Final. - Oct 31, 2005 It is my privilege today to introduce Dr. Mark Pimentel, the Principal Investigator for and investigator initiated study of Xifaxan in treatment of ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Antibiotic Relieves Chronic Bloating and Flatulence - Feb 15, 2006 15 - Chronic abdominal bloating and flatulence may have salvation in the antibiotic Xifaxan (rifaximin), which is approved in the US for travelers' diarrhea ... MedPage Today Updates, advisories and surprises - Aug 22, 2005 Salix Pharma ends Xifaxan promotion deal; reaffirms view (9:13 AM ET) NEW YORK (MarketWatch) -- Salix Pharmaceuticalssaid Monday that it's terminated a ... MarketWatch Caffeine Abuse May Be a Problem in Young People - Oct 17, 2006 However, the number of patients in the study was small, only 87, so more research is needed to know whether Xifaxan is truly beneficial for people with IBS. ... ABC News Drug may prevent C-diff recurrence - Dec 28, 2005 Xifaxan, a drug approved to treat several gastrointestinal problems, ... Researchers found that Xifaxan (rifaxamin) protected hamsters against the ... DentalPlans.com Salix swings to loss in 2Q - Aug 4, 2008 Xifaxan sales were up by 14 percent, to $18 million. Bowel cleanser revenue increased 38 percent, to $15.7 million. Salix said it expects to post $43 ... Bizjournals.com warts Immunotherapy may be a ... | Article from The Washington Post |... - May 24, 2005 THIS STUDY randomly assigned 210 adults attending summer classes in Mexico to take rifaximin (Xifaxan) or a placebo for two weeks when they first arrived. ... Pay-Per-View - Washington Post - HighBeam Research rifaximin Altana, Salix licensing agreement.(Pharmaceutical industry)(... - Mar 14, 2005 ...rifaximin, rifaximine, rifaxidin, L 105, L 105SV, XIFAXAN, LUMENAX, NORMIX, RIFACOL, DERMODIS, REDACTIVE, FLONORM, A5B, Hepatic Protectors, Lipotropics, ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Press Release: InterMune Announces Hepatitis C Presentations at … - May 9, 2005 TM) and one investigator-initiated trial of XIFAXAN(R) (rifaximin) tablets 200 mg that were presented today at Digestive Disease Week(R) 2006. ... Pay-Per-View - PR Newswire - HighBeam Research Other News To Note. - Jan 5, 2006 Xifaxan is an oral antibiotic that has been approved for the treatment of traveler's diarrhea caused by non-invasive strains of E. coli in patients 12 years ... Pay-Per-View - BIOWORLD Today - Factiva, from Dow Jones Salix Pharmaceuticals to Present At CIBC World Markets Conference. - Apr 4, 2007 Salix markets COLAZAL([R]), XIFAXAN([R]), OSMOPREP[TM], VISICOL([R]), MOVIPREP([R]), PEPCID([R]) OS, DIURIL([R]) OS, AZASAN([R]), ANUSOL-HC([R]) and ... Free with registration - Business Wire - AccessMyLibrary.com Antibiotic might help abdominal condition - Oct 22, 2006 The drug -- sold for about $200 under the brand name Xifaxan by Salix Pharmaceuticals Inc. -- is not absorbed from the intestine into the rest of the body, ... Pay-Per-View - Orlando Sentinel - ProQuest Archiver DIARRHEA TREATMENT SEEMS TO HELP IN ADVANCE - Jun 21, 2005 This study randomly assigned 210 adults attending summer classes in Mexico to take rifaximin (Xifaxan) or a placebo for two weeks when they first arrived. ... $2.95 - St. Paul Pioneer Press - NewsBank Treatment of IBS with Nonabsorbable Antibiotics - Apr 15, 2007 Overall improvement of irritable bowel syndrome with rifaximin (Xifaxan) during 10 weeks of follow-up on the basis of a mixed multivariate model. ... AAFP News Now Salix Pharmaceuticals Announces Issuance Of MOVIPREP(R) Patent - Jan 31, 2007 Salix markets COLAZAL(R), XIFAXAN(R), OSMOPREP(TM), VISICOL(R), MOVIPREP(R) , AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). Balsalazide tablets, Granulated ... Genetic Engineering News - Genetic Engineering News (press release) Salix Pharmaceuticals Receives Approvable Letter from FDA for … - May 19, 2008 Salix markets COLAZAL® (balsalazide disodium) Capsules 750 mg, XIFAXAN® (rifaximin) tablets 200 mg , OSMOPREP® (sodium phosphate monobasic monohydrate, ... carolinanewswire.com Colazal(R) Pediatric Indication Approved. - Dec 20, 2006 Salix also markets XIFAXAN([R]), VISICOL([R]), OSMOPREP[TM], MOVIPREP([R]), AZASAN([R]), ANUSOL-HC([R]) and PROCTOCORT([R]). Balsalazide tablets, Granulated ... Free with registration - Business Wire - AccessMyLibrary.com Traveler's diarrhea. - Jun 1, 2005 Rifaximin (Xifaxan) 200 mg three times daily for three days ... Rifaximin (Xifaxan) Not effective in persons with dysentery ... Pay-Per-View - American Family Physician - Factiva, from Dow Jones Traveler's diarrhea. - Jun 1, 2005 ...(23) Rifaximin (Xifaxan) may prove to be the preferred antibiotic because it is ... Rifaximin (Xifaxan) Not effective in persons with dysentery Azithromycin ... $4.95 - American Family Physician - ECNext Salix Pharmaceuticals to Present at Wachovia Securities Healthcare … - Jan 24, 2007 Salix markets COLAZAL([R]), XIFAXAN([R]), OSMOPREP[TM], VISICOL([R]), MOVIPREP([R]), AZASAN([R]), ANUSOL-HC([R]) and PROCTOCORT([R]). ... Free with registration - Business Wire - AccessMyLibrary.com OsmoPrep(TM) Tablets Granted FDA Marketing Approval; New Tablet … - Mar 17, 2006 OsmoPrep, Colazal(R) and Xifaxan(R), Salix's three primary growth drivers, now combine to create the focus of our product portfolio. ... Free with registration - Business Wire - AccessMyLibrary.com Salix Pharmaceuticals granted MHRA marketing approval for Diacol … - Dec 13, 2006 Salix also markets COLAZAL®, XIFAXAN®, VISICOL®, MOVIPREP®, AZASAN®, ANUSOL-HC® and PROCTOCORT®. Balsalazide tablets, Granulated Mesalamine, SANVAR® (600 ug ... carolinanewswire.com Salix Pharmaceuticals Announces 3Q2006 Financial Results Conference … - Oct 24, 2006 Salix also markets XIFAXAN(R), VISICOL(R), OSMOPREP(TM), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). In August 2006, the FDA approved MOVIPREP(R) for bowel ... Genetic Engineering News - Genetic Engineering News (press release) Salix Pharmaceuticals Announces Positive Top Line Results of … - Jun 18, 2007 Salix also markets XIFAXAN([R]) (rifaximin) tablets 200 mg , OSMOPREP[TM] Tablets (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic ... Free with registration - Business Wire - AccessMyLibrary.com Salix Pharmaceuticals Announces 1Q2007 Financial Results Conference … - Apr 24, 2007 Balsalazide disodium tablets, Granulated Mesalamine, SANVAR([R]) (600 ug vials vapreotide acetate powder) and Xifaxan are under development for additional ... Free with registration - Business Wire - AccessMyLibrary.com Salix Pharmaceuticals to Present at Three Investment Conferences … - May 2, 2007 Salix markets COLAZAL([R]), XIFAXAN([R]), OSMOPREP[TM], VISICOL([R]), MOVIPREP([R]), PEPCID([R]) OS, DIURIL([R]) OS, AZASAN([R]), ANUSOL-HC([R]) and ... Free with registration - Business Wire - AccessMyLibrary.com |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |